197 related articles for article (PubMed ID: 36718618)
1. Factor XI inhibitors: what should clinicians know.
Pandey A; Verma R; Eikelboom J; Verma S
Curr Opin Cardiol; 2023 Mar; 38(2):88-93. PubMed ID: 36718618
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology and Clinical Development of Factor XI Inhibitors.
Greco A; Laudani C; Spagnolo M; Agnello F; Faro DC; Finocchiaro S; Legnazzi M; Mauro MS; Mazzone PM; Occhipinti G; Rochira C; Scalia L; Capodanno D
Circulation; 2023 Mar; 147(11):897-913. PubMed ID: 36913497
[TBL] [Abstract][Full Text] [Related]
3. Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review.
Prakash S; Mares AC; Porres-Aguilar M; Mukherjee D; Barnes GD
Vasc Med; 2024 Feb; 29(1):85-92. PubMed ID: 37947131
[TBL] [Abstract][Full Text] [Related]
4. New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors.
Chan NC; Weitz JI
Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):1755-1763. PubMed ID: 37650326
[TBL] [Abstract][Full Text] [Related]
5. Factor XI: structure, function and therapeutic inhibition.
Ali AE; Becker RC
J Thromb Thrombolysis; 2024 Apr; ():. PubMed ID: 38622277
[TBL] [Abstract][Full Text] [Related]
6. Factor XI antisense oligonucleotide for prevention of venous thrombosis.
Büller HR; Bethune C; Bhanot S; Gailani D; Monia BP; Raskob GE; Segers A; Verhamme P; Weitz JI;
N Engl J Med; 2015 Jan; 372(3):232-40. PubMed ID: 25482425
[TBL] [Abstract][Full Text] [Related]
7. Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease.
Ades M; Simard C; Vanassche T; Verhamme P; Eikelboom J; Mavrakanas TA
Semin Nephrol; 2023 Nov; 43(6):151484. PubMed ID: 38272779
[TBL] [Abstract][Full Text] [Related]
8. Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery-Systematic review and meta-analysis.
Presume J; Ferreira J; Ribeiras R; Mendes M
J Thromb Haemost; 2022 Dec; 20(12):2930-2938. PubMed ID: 36128769
[TBL] [Abstract][Full Text] [Related]
9. A new strategy for anticoagulation: The factor XI inhibitors.
Vedovati MC; Becattini C; Agnelli G
Eur J Intern Med; 2023 Oct; 116():8-15. PubMed ID: 37544845
[TBL] [Abstract][Full Text] [Related]
10. [Factor XI inhibitors: the holy grail of anticoagulant therapy?].
Harskamp RE; Middeldorp S; De Groot JR
Ned Tijdschr Geneeskd; 2022 Nov; 166():. PubMed ID: 36633082
[TBL] [Abstract][Full Text] [Related]
11. Factor XI inhibitors for the prevention of cardiovascular disease: A new therapeutic approach on the horizon?
Santagata D; Donadini MP; Ageno W
Blood Rev; 2023 Nov; 62():101119. PubMed ID: 37580207
[TBL] [Abstract][Full Text] [Related]
12. Targeting factor XI and factor XIa to prevent thrombosis.
Gailani D; Gruber A
Blood; 2024 Apr; 143(15):1465-1475. PubMed ID: 38142404
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
Zhang H; Löwenberg EC; Crosby JR; MacLeod AR; Zhao C; Gao D; Black C; Revenko AS; Meijers JC; Stroes ES; Levi M; Monia BP
Blood; 2010 Nov; 116(22):4684-92. PubMed ID: 20807891
[TBL] [Abstract][Full Text] [Related]
14. Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives.
Vlădăreanu AM; Roşca A
Rom J Intern Med; 2024 Jun; 62(2):91-100. PubMed ID: 38153875
[TBL] [Abstract][Full Text] [Related]
15. Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials.
Daghlas I; Gill D
Eur J Neurol; 2023 Jul; 30(7):2112-2116. PubMed ID: 37038320
[TBL] [Abstract][Full Text] [Related]
16. Factor XI Inhibition for the Prevention of Venous Thromboembolism: An Update on Current Evidence and Future perspectives.
Poenou G; Dumitru Dumitru T; Lafaie L; Mismetti V; Heestermans M; Bertoletti L
Vasc Health Risk Manag; 2022; 18():359-373. PubMed ID: 35707632
[TBL] [Abstract][Full Text] [Related]
17. Factor XI inhibitors: cardiovascular perspectives.
De Caterina R; Prisco D; Eikelboom JW
Eur Heart J; 2023 Jan; 44(4):280-292. PubMed ID: 36263776
[TBL] [Abstract][Full Text] [Related]
18. Future of factor XI inhibitors in cardiovascular practice.
Greco A; Ammirabile N; Landolina D; Imbesi A; Raffo C; Capodanno D
Minerva Cardiol Angiol; 2024 May; ():. PubMed ID: 38804623
[TBL] [Abstract][Full Text] [Related]
19. A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors.
Salomon O; Gailani D
J Thromb Haemost; 2022 Jan; 20(1):32-38. PubMed ID: 34735741
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Factor XI: A New Era in the Treatment of Venous Thromboembolism in Cancer Patients?
Poenou G; Heestermans M; Lafaie L; Accassat S; Moulin N; Rodière A; Petit B; Duvillard C; Mismetti P; Bertoletti L
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
